Last checked at 
Hemogenyx Pharmaceuticals PLC - London-based biotechnology firm - Continuing development of Covid-19 medication. Says subsidiary Immugenyx LLC will take cells from blood samples of former Covid-19 sufferers and transplant them into advanced peripheral blood hematopoietic chimera or advanced humanised mice. Hemogenyx says process will allow scientists to recreate virus antibodies.
Current stock price: 5.65 pence
Year-to-date change: up almost threefold from 1.93p on January 2
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.